Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 183

1.

Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.

Hoot S, McGuire AT, Cohen KW, Strong RK, Hangartner L, Klein F, Diskin R, Scheid JF, Sather DN, Burton DR, Stamatatos L.

PLoS Pathog. 2013 Jan;9(1):e1003106. doi: 10.1371/journal.ppat.1003106. Epub 2013 Jan 3. Erratum in: PLoS Pathog. 2013 Jul;9(9). doi:10.1371/annotation/ed7c0148-97eb-4416-824d-6e6d1aaeceef.

PMID:
23300456
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.

McGuire AT, Glenn JA, Lippy A, Stamatatos L.

J Virol. 2014 Mar;88(5):2645-57. doi: 10.1128/JVI.03228-13. Epub 2013 Dec 18.

PMID:
24352455
[PubMed - indexed for MEDLINE]
Free PMC Article
3.
4.

Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies.

McGuire AT, Hoot S, Dreyer AM, Lippy A, Stuart A, Cohen KW, Jardine J, Menis S, Scheid JF, West AP, Schief WR, Stamatatos L.

J Exp Med. 2013 Apr 8;210(4):655-63. doi: 10.1084/jem.20122824. Epub 2013 Mar 25.

PMID:
23530120
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: differences from the human counterparts and implications for HIV-1 vaccine development.

Yuan T, Li J, Zhang Y, Wang Y, Streaker E, Dimitrov DS, Zhang MY.

Vaccine. 2011 Sep 16;29(40):6903-10. doi: 10.1016/j.vaccine.2011.07.046. Epub 2011 Jul 30.

PMID:
21807049
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site.

Sundling C, Li Y, Huynh N, Poulsen C, Wilson R, O'Dell S, Feng Y, Mascola JR, Wyatt RT, Karlsson Hedestam GB.

Sci Transl Med. 2012 Jul 11;4(142):142ra96. doi: 10.1126/scitranslmed.3003752.

PMID:
22786681
[PubMed - indexed for MEDLINE]
Free Article
7.

HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies.

McGuire AT, Dreyer AM, Carbonetti S, Lippy A, Glenn J, Scheid JF, Mouquet H, Stamatatos L.

Science. 2014 Dec 12;346(6215):1380-3. doi: 10.1126/science.1259206.

PMID:
25504724
[PubMed - indexed for MEDLINE]
8.

Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.

Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, Wang Y, Zhang MY, Longo NS, Dimitrov DS.

Biochem Biophys Res Commun. 2009 Dec 18;390(3):404-9. doi: 10.1016/j.bbrc.2009.09.029. Epub 2009 Sep 11.

PMID:
19748484
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Anti-HIV B Cell lines as candidate vaccine biosensors.

Ota T, Doyle-Cooper C, Cooper AB, Huber M, Falkowska E, Doores KJ, Hangartner L, Le K, Sok D, Jardine J, Lifson J, Wu X, Mascola JR, Poignard P, Binley JM, Chakrabarti BK, Schief WR, Wyatt RT, Burton DR, Nemazee D.

J Immunol. 2012 Nov 15;189(10):4816-24. doi: 10.4049/jimmunol.1202165. Epub 2012 Oct 12.

PMID:
23066156
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.

deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, Gottardo R, Edlefsen P, Self S, Tang H, Greene K, Gao H, Daniell X, Sarzotti-Kelsoe M, Gorny MK, Zolla-Pazner S, LaBranche CC, Mascola JR, Korber BT, Montefiori DC.

J Virol. 2014 Mar;88(5):2489-507. doi: 10.1128/JVI.02853-13. Epub 2013 Dec 18.

PMID:
24352443
[PubMed - indexed for MEDLINE]
Free PMC Article
11.
12.

Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.

Sharma VA, Kan E, Sun Y, Lian Y, Cisto J, Frasca V, Hilt S, Stamatatos L, Donnelly JJ, Ulmer JB, Barnett SW, Srivastava IK.

Virology. 2006 Aug 15;352(1):131-44. doi: 10.1016/j.virol.2006.04.030.

PMID:
21894641
[PubMed - indexed for MEDLINE]
Free Article
13.

Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.

Zhang MY, Xiao X, Sidorov IA, Choudhry V, Cham F, Zhang PF, Bouma P, Zwick M, Choudhary A, Montefiori DC, Broder CC, Burton DR, Quinnan GV Jr, Dimitrov DS.

J Virol. 2004 Sep;78(17):9233-42.

PMID:
15308718
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein.

Dey AK, Burke B, Sun Y, Sirokman K, Nandi A, Hartog K, Lian Y, Geonnotti AR, Montefiori D, Franti M, Martin G, Carfi A, Kessler P, Martin L, Srivastava IK, Barnett SW.

PLoS One. 2012;7(1):e30233. doi: 10.1371/journal.pone.0030233. Epub 2012 Jan 24.

PMID:
22291921
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity.

Kobie JJ, Alcena DC, Zheng B, Bryk P, Mattiacio JL, Brewer M, Labranche C, Young FM, Dewhurst S, Montefiori DC, Rosenberg AF, Feng C, Jin X, Keefer MC, Sanz I.

PLoS One. 2012;7(4):e35356. doi: 10.1371/journal.pone.0035356. Epub 2012 Apr 18.

PMID:
22530008
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits.

Yasmeen A, Ringe R, Derking R, Cupo A, Julien JP, Burton DR, Ward AB, Wilson IA, Sanders RW, Moore JP, Klasse PJ.

Retrovirology. 2014 May 29;11:41. doi: 10.1186/1742-4690-11-41.

PMID:
24884783
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.

Utachee P, Isarangkura-na-ayuthaya P, Tokunaga K, Ikuta K, Takeda N, Kameoka M.

Retrovirology. 2014 Apr 23;11:32. doi: 10.1186/1742-4690-11-32.

PMID:
24758333
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1.

Liao HX, Tsao CY, Alam SM, Muldoon M, Vandergrift N, Ma BJ, Lu X, Sutherland LL, Scearce RM, Bowman C, Parks R, Chen H, Blinn JH, Lapedes A, Watson S, Xia SM, Foulger A, Hahn BH, Shaw GM, Swanstrom R, Montefiori DC, Gao F, Haynes BF, Korber B.

J Virol. 2013 Apr;87(8):4185-201. doi: 10.1128/JVI.02297-12. Epub 2013 Jan 30.

PMID:
23365441
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop.

Ching L, Stamatatos L.

J Virol. 2010 Oct;84(19):9932-46. doi: 10.1128/JVI.00868-10. Epub 2010 Jul 21.

PMID:
20660181
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk